Literature DB >> 17945187

Inter-conversion of neuregulin2 full and partial agonists for ErbB4.

Kristy J Wilson1, Christopher P Mill, Elizabeth M Cameron, Stuart S Hobbs, Robert P Hammer, David J Riese.   

Abstract

The EGF family hormone NRG2beta potently stimulates ErbB4 tyrosine phosphorylation and coupling to IL3 independence. In contrast, the NRG2alpha splicing isoform has lower affinity for ErbB4, does not potently stimulate ErbB4 phosphorylation, and fails to stimulate ErbB4 coupling. Here we investigate these differences. The NRG2beta Q43L mutant potently stimulates ErbB4 phosphorylation but not ErbB4 coupling to IL3 independence. This failure to stimulate ErbB4 coupling is not due to differential ligand purity, glycosylation, or stability. The NRG2alpha K45F mutant potently stimulates ErbB4 phosphorylation but not ErbB4 coupling to IL3 independence. Thus, this failure to stimulate ErbB4 coupling is not due to inadequate affinity for ErbB4. In contrast, the NRG2alpha L43Q/K45F mutant stimulates ErbB4 coupling, even though it does not have greater affinity for ErbB4 than does NRG2alpha/K45F. Collectively, these data indicate that Gln43 of NRG2beta is both necessary and sufficient for NRG2 stimulation of ErbB4 coupling to IL3 independence.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17945187      PMCID: PMC2094732          DOI: 10.1016/j.bbrc.2007.10.004

Source DB:  PubMed          Journal:  Biochem Biophys Res Commun        ISSN: 0006-291X            Impact factor:   3.575


  23 in total

Review 1.  EGF-ERBB signalling: towards the systems level.

Authors:  Ami Citri; Yosef Yarden
Journal:  Nat Rev Mol Cell Biol       Date:  2006-07       Impact factor: 94.444

2.  Stimulation of acetylcholine receptor transcription by neuregulin-2 requires an N-box response element and is regulated by alternative splicing.

Authors:  O N Ponomareva; H Ma; R Dakour; T D Raabe; C Lai; M Rimer
Journal:  Neuroscience       Date:  2005       Impact factor: 3.590

3.  The cellular response to neuregulins is governed by complex interactions of the erbB receptor family.

Authors:  D J Riese; T M van Raaij; G D Plowman; G C Andrews; D F Stern
Journal:  Mol Cell Biol       Date:  1995-10       Impact factor: 4.272

4.  Phe45 of NRG2beta is critical for the affinity of NRG2beta for ErbB4 and for potent stimulation of ErbB4 signaling by NRG2beta*.

Authors:  Stuart S Hobbs; Richard M Gallo; David J Riese
Journal:  Growth Factors       Date:  2005-12       Impact factor: 2.511

5.  Differential effects of amphiregulin and TGF-alpha on the morphology of MDCK cells.

Authors:  Eunkyung Chung; Ramona Graves-Deal; Jeffrey L Franklin; Robert J Coffey
Journal:  Exp Cell Res       Date:  2005-09-10       Impact factor: 3.905

6.  The epidermal growth factor receptor (EGFR)-S442F mutant displays increased affinity for neuregulin-2beta and agonist-independent coupling with downstream signalling events.

Authors:  Jennifer L Gilmore; Richard M Gallo; David J Riese
Journal:  Biochem J       Date:  2006-05-15       Impact factor: 3.857

Review 7.  The ErbB receptors and their ligands in cancer: an overview.

Authors:  N Normanno; C Bianco; L Strizzi; M Mancino; M R Maiello; A De Luca; F Caponigro; D S Salomon
Journal:  Curr Drug Targets       Date:  2005-05       Impact factor: 3.465

8.  Epidermal growth factor receptor dimerization and activation require ligand-induced conformational changes in the dimer interface.

Authors:  Jessica P Dawson; Mitchell B Berger; Chun-Chi Lin; Joseph Schlessinger; Mark A Lemmon; Kathryn M Ferguson
Journal:  Mol Cell Biol       Date:  2005-09       Impact factor: 4.272

9.  Betacellulin activates the epidermal growth factor receptor and erbB-4, and induces cellular response patterns distinct from those stimulated by epidermal growth factor or neuregulin-beta.

Authors:  D J Riese; Y Bermingham; T M van Raaij; S Buckley; G D Plowman; D F Stern
Journal:  Oncogene       Date:  1996-01-18       Impact factor: 9.867

Review 10.  Signaling through ERBB receptors: multiple layers of diversity and control.

Authors:  Carmen M Warren; Ralf Landgraf
Journal:  Cell Signal       Date:  2006-02-07       Impact factor: 4.315

View more
  11 in total

Review 1.  Epiregulin: roles in normal physiology and cancer.

Authors:  David J Riese; Richard L Cullum
Journal:  Semin Cell Dev Biol       Date:  2014-03-12       Impact factor: 7.727

Review 2.  EGFR ligands exhibit functional differences in models of paracrine and autocrine signaling.

Authors:  Kristy J Wilson; Christopher Mill; Sydney Lambert; Jennifer Buchman; Timothy R Wilson; Victor Hernandez-Gordillo; Richard M Gallo; Laura M C Ades; Jeffrey Settleman; David J Riese
Journal:  Growth Factors       Date:  2012-01-20       Impact factor: 2.511

3.  The Q43L mutant of neuregulin 2β is a pan-ErbB receptor antagonist.

Authors:  Kristy J Wilson; Christopher P Mill; Richard M Gallo; Elizabeth M Cameron; Henry VanBrocklin; Jeffrey Settleman; David J Riese
Journal:  Biochem J       Date:  2012-04-01       Impact factor: 3.857

4.  ErbB2 Is Necessary for ErbB4 Ligands to Stimulate Oncogenic Activities in Models of Human Breast Cancer.

Authors:  Christopher P Mill; Michael D Zordan; S Michael Rothenberg; Jeffrey Settleman; James F Leary; David J Riese
Journal:  Genes Cancer       Date:  2011-08

5.  A high throughput, interactive imaging, bright-field wound healing assay.

Authors:  Michael D Zordan; Christopher P Mill; David J Riese; James F Leary
Journal:  Cytometry A       Date:  2011-02-09       Impact factor: 4.355

6.  Ligand-based receptor tyrosine kinase partial agonists: New paradigm for cancer drug discovery?

Authors:  David J Riese
Journal:  Expert Opin Drug Discov       Date:  2011-02       Impact factor: 6.098

7.  Mechanism of activation and inhibition of the HER4/ErbB4 kinase.

Authors:  Chen Qiu; Mary K Tarrant; Sung Hee Choi; Aruna Sathyamurthy; Ron Bose; Sudeep Banjade; Ashutosh Pal; William G Bornmann; Mark A Lemmon; Philip A Cole; Daniel J Leahy
Journal:  Structure       Date:  2008-03       Impact factor: 5.006

8.  Activation of ErbB3, EGFR and Erk is essential for growth of human breast cancer cell lines with acquired resistance to fulvestrant.

Authors:  Thomas Frogne; Rikke V Benjaminsen; Katrine Sonne-Hansen; Boe S Sorensen; Ebba Nexo; Anne-Vibeke Laenkholm; Louise M Rasmussen; David J Riese; Patricia de Cremoux; Jan Stenvang; Anne E Lykkesfeldt
Journal:  Breast Cancer Res Treat       Date:  2008-04-14       Impact factor: 4.872

Review 9.  Functional selectivity of EGF family peptide growth factors: implications for cancer.

Authors:  Kristy J Wilson; Jennifer L Gilmore; John Foley; Mark A Lemmon; David J Riese
Journal:  Pharmacol Ther       Date:  2008-12-16       Impact factor: 12.310

10.  A Two-Stage Whole-Genome Gene Expression Association Study of Young-Onset Hypertension in Han Chinese Population of Taiwan.

Authors:  Kuang-Mao Chiang; Hsin-Chou Yang; Wen-Harn Pan
Journal:  Sci Rep       Date:  2018-01-29       Impact factor: 4.379

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.